Physician profile
Vesta Ackernecht
NPI 1114793684
$677.50
in general payments reported to CMS, 2019-2025
12 companies · $466 in 2025
The $466 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $211 · 2025: $466.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $678.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $677.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $149.79 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Lilly USA, LLC | $95.47 | 2024-2025 | Zepbound, Mounjaro, Jardiance |
| Braeburn INC. | $90.82 | 2024-2025 | Brixadi |
| Astellas Pharma US INC | $57.34 | 2025 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $52.78 | 2025 | |
| Merck Sharp & Dohme LLC | $45.66 | 2024-2025 | Gardasil 9, Vaxneuvance, Capvaxive |
| Otsuka America Pharmaceutical, INC. | $40.48 | 2024 | Rexulti |
| Medtronic, INC. | $34.79 | 2025 | Minimed 780g |
| Sanofi-Aventis U.S. LLC | $34.58 | 2025 | |
| Indivior INC. | $33.27 | 2024-2025 | Sublocade |
| Abbvie INC. | $21.38 | 2025 | |
| Glaxosmithkline, LLC. | $21.14 | 2025 | Bexsero |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vesta Ackernecht listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.